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It is widely accepted that the presence and the levels of expression of class I
MHC antigens on virus-infected and tumor cells are of crucial importance for
recognition by T lymphocytes, particularly cytolytic T lymphocytes (CTL). In
that tumors frequently exhibit low constitutive levels of MHC expression, the
ability of the interferons, especially IFN-y, to upregulate MHC expression may
thus become critical to successful immune recognition and elimination of such
unwanted cells. On the other hand, the ability of a neoplastic cell to eliminate
class I expression or to lower constitutive levels of class I-restricting elements
for CTL, coupled with a resistance to the enhancing effects of IFN, might pro-
vide an escape mechanism from immune recognition that would confer a selec-
tive advantage for tumor establishment.
We have been interested in the interaction of specific antiviral CTL with
tumors induced by AKR/Gross murine leukemia viruses (MuLV)' with respect
to the recognition of both viral antigens and the H-2K class I-restricting ele-
ment used in this system (1-4). Recently, we identified two MuLV+ tumors of
the high leukemia incidence H-2k haplotype that showed an unusual phenotype
with regard to class I expression after IFN-y treatment. In contrast to normal
cells and most tumor lines, where there is a coordinate induction or augmen-
tation of the expression of class I antigens, in these two tumors only H-2D', not
H-2Kk expression was augmented by IFN-y (5) or IFN-a (Green, W. R., et al.,
unpublished observations). The lack of induction of Kk was found not to be
dependent on a particular dose of IFN-y or time of treatment, and the low but
significant constitutive levels of Kk expression argued against a deletion or gen-
eral inactivation of the K k gene . In addition, the augmentation of Dk expression
indicated that IFN-y was binding to the cells, resulting in signal transmission.
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The present study addresses the mechanism behind this differential induction
of class I genes in one of these two tumors, the AKR SL3 line. Although IFN
signaling of class I genes is generally believed to occur primarily at the transcrip-
tional level (6, 7), IFN regulation appears to be complex. A number of cis-acting
regulatory sequences have recently been described for IFN-y and/or IFN-a/0
(8-10) . In many cases, however, the magnitude of the effects dictated by these
sequences only partially accounted for the increases in cell surface expression
of class I protein. In addition, there are several reports of trans-acting factors
that are involved in the control of class I expression (11, 12). In this commu-
nication we report our initial attempts to define the mechanism by which the Kk
gene of the AKR SL3 line is resistant to IFN-y augmentation by considering cis-
dominant vs. trans-acting alterations. To differentiate between these two possi-
bilities, T-T tumor hybrid cell lines were constructed between the AKR SL3 line
and a T tumor line of a distinguishable H-2 haplotype that shows normal aug-
mentation of both K and D class I antigens in response to IFN-y treatment.
Materials and Methods
IFN-y.
￿
Murine rIFN-y produced by Escherichia coli that had been transfected with
the DNA coding sequence for IFN-y was kindly supplied courtesy of Dr. H. Michael
Shepard, by Genetech, Inc., South San Francisco, CA, and was used at a concentration
of 100 U/ml in tissue culture medium (TC).
Cell Culture Media.
￿
All parental tumors and hybrids were passaged in TC consisting
of RPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 10% FCS
(Hyclone Laboratories, Logan, UT), antibiotics, 2 mM glutamine, and 50 AM 2-ME
(Sigma Chemical Co., St. Louis, MO).
H-2-specific Antibodies.
￿
HB19, specific for H-2Db; and HB41, specific for H-W; are
IgM mAbs used as supernatant and concentrated supernatant, respectively, whose cor-
responding hybridomas were obtained from the American Type Culture Collection,
Rockville, MD. Hybridoma cells for mAb 15-5-5S, IgG2a anti-H-21)k' were kindly pro-
vided by Dr. K. Ozato (National Institutes of Health, Bethesda, MD). mAb 11-4.1, IgG2a
anti-H-2Kk, was used as an ascites preparation and was kindly provided by Dr. R. C.
Nowinski (Genetic Systems, Seattle, WA) . IgM SCC (anti-human small cell carcinoma of
the lung), IgM 35/12 (anti-DNP, gift of Dr. R. Noelle, Dartmouth), and IgG2a OKT8
were used as negative control mAbs.
Drug Marking of Parental Tumor Cells and T Tumor Fusions.
￿
E Y Kl, a tumor of
C57BL/6 (H-2b) origin (13), was drug marked by growing the cells in TC medium con-
taining dialyzed FCS and 67 Ag/ml of 5-bromo-deoxyuridine (BUdR, Sigma Chemical
Co.). A drug-resistant clone obtained by limiting dilution, E 4 KI-cl.B2-BUdR', was used
as the H-2b parental partner in all fusions. SL3, a tumor line of AKR (H-2k) origin (13),
was drug marked with 1 .5 Ag/ml of 8-azaguanine (AZ, Sigma Chemical Co.), yielding the
AKR SL3-AZ' line used in fusions 1 and 2. This line was subsequently exposed to 100
U/ml of IFN-y for 6 d followed by a one cell per well sterile sort for optimal Dk antigen
expression (for details on sorting see analogous hybrid Kb sorting discussed below), yield-
ing clones including AKR SL3-cl.F-AZ', which was used as the H-2k parental tumor in
fusion 3 . For hybrid formation, between 4 X 106 and 1 X 107 T tumor fusion partner
cells were used at 1 :1 ratio using PEG 1500 (Boehringer Mannheim Biochemicals, Indi-
anapolis, IN). Selection for hybrids was carried out in TC supplemented with hypoxan-
thine, aminopterin, and thymidine (HAT, Sigma Chemical Co.).
Indirect Immunofluorescence, Sorting, Two-ColorAnalysis.
￿
To ensure their general recep-
tiveness to IFN-y signaling of MHC expression, T tumor hybrids from fusions 1 and 2
were exposed to 100 U/ml of IFN-y for 6-7 d with daily medium change. Whereas all
hybrids tested showed significant augmentation of Dk and Kb expression, confirming that
chromosome(s) 17 of both parental types were present, the brightest 0.1-0.5% of hybrids1618
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expressing Kb were sterilely sorted to one cell per well. After 10-14 d clones were
sequentially weaned from HAT to TC medium, and in some cases underwent an exten-
sive two color-analysis using a cytofluorograph (Ortho Diagnostic Systems Inc., West-
wood, MA) (Table I). Kb expression was detected using mAb HB41 followed by
FITC-conjugated goat anti-mouse y chain-specific serum (Boehringer Mannheim Bio-
chemicals) . Dk expression was detected using mAb 15-5-5S followed by R-Phycoerythrin
(PE)-conjugated goat anti-mouse y chain-specific serum (Southern Biotechnology Asso-
ciates, Inc., Birmingham, AL) . Correction factors were used that effectively eliminated
green color bleeding into red or vice versa. For analysis of H-2Kb, Db, Kk, and Dk antigen
expression without and after IFN-y exposure for 6-7 d, hybrid and parental tumor lines
were incubated sequentially with various dilutions of control or anti-H-2 mAb followed
by FITC-labeled goat F(ab'), anti-mouse IgG, IgA, IgM, H chain- and I, chain-specific
antiserum (Cooper Biomedical, Inc., Malvern, PA) before analysis on the
cytofluorograph.
Results and Discussion
To construct hybrids, E 4 Kl-e1.B2-BUdRR, a BUdR-resistant subline of the
C57BL/6 (H-2b) thymoma, was fused with the AZ-resistant AKR SL3-AZR(H-2k)
variant with PEG followed by HAT selection. These parental lines were unable
to grow in the opposite drug or in HAT-containing medium. Two-color immu-
nofluorescence and flow cytometry were used to confirm the hybrid nature of
the fused cells and their retention of chromosomes encoding both parental
MHC haplotypes. In contrast to the parental tumor lines, a substantial percent-
age (up to 99% of cells for the five hybrids tested in Table I, and all additional
hybrids tested, including fusion 3 below), expressed both Kb and Dk antigens.
This was particularly apparent for some hybrids after their low-to-moderate
parental levels of constitutive expression were boosted by IFN-y treatment .
Indeed, 97-99% of the cells of these hybrids then simultaneously expressed
both easily detectable Kb and Dk. The enchancement of MHC expression by all
hybrids after IFN-y treatment also confirmed their receptiveness to IFN acti-
vation. Mixtures of hybrid cells stained separately for their Kb or Dk antigens or
mixtures of parental tumor cells stained for their respective class I antigens
resulted in minimal percentages of cells scored as "double positives." In addi-
tion, the failure to detect both Kb and Dk on the parental tumors confirmed the
lack of crossreaetivity of the monoclonals used.
Hybrid clones from two independent fusions were next treated with IFN-y,
and the expression of all four class I MHC antigens was assessed separately by
one-color flow cytometric analysis. IFN-y treatment resulted in substantial
increases in the percentages of positive cells and/or in the total mean fluores-
cence for Db, Kb, and Dk antigens for all hybrids tested (Table II). In sharp con-
trast, the expression of Kk by the hybrids, like that by the parental AKR SL3
line, selectively showed little or no change after IFN-y treatment. In particular,
the stimulation of Kb expression was often dramatic, suggesting that if an IFN-
y-triggered, positive-acting, K locus-specific factor existed, it should have been
readily available to augment Kk expression. In addition, it should be noted that,
although the constitutive levels of the different class I antigens varied, fre-
quently the constitutive level of Kk expression was similar to that of the aug-
mentable Kb and/or Dk genes. This pattern of results was remarkably reproduc-
ible, as shown by the summarized fold increase data for Exp. 2 (Table II) . InGREEN ET AL.
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TABLE I
Flow Cytometric Evidence That HAT-selected TumorCells Are Hybrids and Express Both
Inducible H-2°and H-2" Class I MHCAntigens
Hybrid (fusion 1) andhybrid andparental (fusion 2) tumorcellswere stained for K' andDkantigen
expression simultaneously, both without and after exposure to 100 U/ml IFN for 6-7 d. The per-
cent positive cells and theirtotal mean fluorescence intensity (TMFI, linear scale 0-200) are listed.
Negative control staining with isotype-matched mAbs averaged 4.2%.
*The percent of cells, which were plotted to points within a region of histogram P4 (HP4), where
both K° and Dk antigens were detected. For fusion 1 this region was defined by mixing hybrids
stained with either anti-H-2K°or H-2D' antibodies at a 1:1 ratiowhereby <7%of cellswere plotted
to region HP4. For fusion 2, a mixture of the two parental lines, stained with anti-H-2K' and H-
2Dk simultaneously followed by correspondingsecond antibodies, were plotted such that <6% of
the cells fell within region HP4. For more details see Materials and Methods.
addition, the three other hybrids from fusions 1 and 2 that were studied also
showed the same differential lack of augmentation of Kk expression, consistent
with a cis-acting alteration.
For fusions 1 and 2 we used a drug-marked population of AKR SL3 tumor
cells in an attempt to utilize a source of cells as related as possible to the original
AKR SL3 line, with which we demonstrated differential class I augmentation by
IFN-'y (5). Because of possible heterogeneity in the AKR SL3 line, which had
not been recently cloned, it was difficult to quantitatively compare the hybrid
clones of fusions 1 and 2 with this H-2k parent. That is, each hybrid resulted
from a fusion of the E 4 KI partner with a single AKR SL3 cell, but there was
no way to identify that particular AKR SL3 parental cell per se for comparison
purposes. Even though the number of hybrids analyzed, all with similar IFN-,y
responsiveness, argued against a skewing of results due to a nonrandom selec-
tion of H-2k fusion partners, a third fusion was performed with a clonal source
of AKR SL3 AZ-resistant cells, AKR SL3-cl.F-AZR. Several resulting hybrids
were tested after IFN-y treatment (Table III) . Again, all hybrids showed sub-
stantial and repeatable increases in all class I MHC antigens except Kk, confirm-
ing our observations above. Five additional hybrids derived from fusion 3 were
also tested with a very similar pattern of reproducible results (data not shown).
These data, obtained through the detailed analysis of 16 hybrid cell lines
Hybrid tumors IFN-y
K°
Positive TMFI
D
k
Positive TMFI
K", D'
Positive*
Fl-1-E - 61 17 38 18 74
+ 99 142 97 83 99
F2-1-A - 32 9 91 49 49
+ 99 85 99 150 98
F2-1-D - 99 60 100 130 99
+ ND ND ND ND ND
172-1 -F - 46 11 86 81 35
+ 98 64 100 152 97
Parental tumors
E 9 K1-cl.B2-BUdRR - 36 12 2 3 0
+ 99 119 0 1 0
AKR SL3 AZR - 0 1 60 35 1
+ 0 1 92 98 61620
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TABLE 11
!FN-y Induced Augmented Expression of IY', K', and Dk, But Not Kk, by Hybrids of the AKR
SL3-AZ" and E-9KI-cl.B2-BUdRH Tumors
Total mean fluorescence
Hybrid tumor clones Antigen IFN-y Positive* Change
in TMFI1
Fold increase§
Fl-1-A Db - 60
+ 86 118 2.5 3.5
Kb _ 8
+ 37 106 20.311 5.2
Dk - 25
+ 66 74 3.4 6.4
Kk - 15
+ 27 6 1.3 <1
Fl-l-E Db - 87
+ 97 112 1 .64 2.4
Kb - 50
+ 96 319 5.4 12.8
Dk - 71
+ 96 158 2.5 8.3
Kk - 24
+ 29 0 <1 <1
F2-1-A Db - 84
+ 99 374 3.4 3.0
Kb - 26
+ 99 460 15.0 15.8
Dk - 5
+ 99 220 5.2 5.5
Kk - 39
+ 36 -9 <1 <1
F2-1-D Db - 99
+ 100 190 1 .64 1.24
Kb - 94
+ 99 318 2.3 2.2
Dk - 96
+ 99 265 2.5 1.24
Kk - 35
+ 24 -11 <1 <1
F2-1-F Db - 90
+ 98 201 2.1 1 .74
Kb - 38
+ 97 299 7.0 6.8
Dk - 58
+ 97 190 3.8 3.1
Kk - 43
+ 40 -3 <1 <1GREEN ET AL.
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TABLE II (Con'd)
ND
ND
For information on the parental hybrids see Materials and Methods.
* The percent of cells staining positive relative to isotype matched negative control mAb staining,
which averaged 4.3% of total cells.
" The change in total mean fluorescence wasdeduced usingthe formula(E; - G,) - (E, - C) where
E; is TMFI of induced experimental cells (i.e., anti-H-2 mAb), C; is TMFI of induced control cells
(i.e., isotype-matched control mAb), E, is TMFI of constitutive experimental cells (i.e., anti-H-2
mAb), Cc is TMFI of constitutive control cells (i.e., isotype-matched control mAb).
§ The fold increase in TMFI was deduced using the formula (E; - G,)l(E, - C). A value of :51
represents a decrease or no change in TMFI with exposure to IFN.
~~ A large IFN-induced change in TMFI sometimes resulted in a very large fold increase when the
constitutive level of expression was low.
4 Conversely, if constitutive expression was high, this mightyield alower fold increase although the
change in TMFI might still be very substantial.
derived equally from fusions using the original AKR SL3 line or a clone of the
latter, were consistent with the existence of an alteration cis to the noninducible
Kk gene. Thus, there was no support for the absence of a K locus-specific, trans-
acting, positive factor as the reason for the unusual differential class I induction
phenotype of AKR SL3. The results are also inconsistent with the presence of
a negative trans-acting regulatory factor. Indeed, the presence of such a K
locus-specific factor in the AKR SL3 line and thus in the hybrids would have
inhibited or tempered the IFN-,y-dependent augmentation of K' gene expres-
sion in the hybrids. Clearly, K' expression was substantially augmented in all
hybrids tested. In addition, although such a negative trans-acting factor need not
be linked to H-2 but could have been encoded on another chromosome that
was selectively not maintained in all the hybrids, the loss of this putative factor
should have resulted in augmentable Kk expression. The data clearly show that
this was not the case. Thus, although more complicated mechanisms involving
multiple alterations may be possible, the most straightforward explanation for
the lack of augmentation of Kk expression in the AKR SL3 line is based on a
cis-acting regulatory defect.
These results, together with our previous identification of a second tumor cell
line that is also MuLV+ and congenic for H-2k (5), are interesting in light of
Hybrid tumor clones Antigen IFN--y Positive*
Total
Change
in TMFI"
mean fluorescence
Fold increase
Parental Tumors
E9KI-cl.B2-BUdR' Db - 97
+ 100 170 1.74
Kb - 84
+ 100 394 4.1
AKR SL3-AZ" D° - 71
+ 92 228 3,4
K' - 45
+ 45 0 <11622
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TABLE III
Lack of Induction ofAugmentedKk Expression by IFN-y in Hybrids of the
AKR SL3-cl. F-AZ' andE .9 K1-cl.B2-BUdRH Tumors
Total mean fluorescence
Exp. 1
￿
Exp. 2
For information on the AKR SL3-cl.F-AZR and E 4 KI-cl.B2-BUdR' parental
clonal tumor lines please see MaterialsandMethods. SeeTable II for explanation
of headings . Isotype-matched negative control mAb staining averaged 6.5%.
*See footnote 11 of Table II legend .
other studies on MHG expression by such tumors . Several studies have sug-
gested aberrant expression of class I antigens by AKR tumors, particularly with
respect to K'` (14-15) . A tumor line described recently by Klyczek et al . (16) that
does not express class I constitutively but also shows a differential induction of
H-2D, not H-2K, antigens by IFN--y is also Gross virus induced and of congenic
Hybrid tumor Antigen IFN--y Positive Change
in TMFI
Fold increase
F3-1-A Db - 53
+ 86 170 2.3
Kb - 8
+ 87 356 12 .1 ND
Dk - 21
+ 75 152 3.5
Kk - 13
+ 13 -1 <1
F3-1-E Db - 44
+ 98 360 4.3 2.5
Kb - 5
+ 95 493 150.5* 12.8
Dk - 11
+ 92 241 6.9 8.3
Kk - 20
+ 17 -11 <1 <1
F3-1-1 Db - 41
+ 97 373 5.3 2.5
K" - 19
+ 97 515 27.8* 17 .1
Dk - 21
+ 87 173 4.9 4.8
Kk - 21
+ 34 -8 <1 <1
Parental tumors
AKR SL3-cl.F- Dk - 65
AZP '
+ 96 328 5.1
Kk - 79 ND
+ 89 25 1 .3H-2k origin . Whether the H-2k haplotype and/or the presence of MuLV expres-
sion has any direct bearing on the differential induction phenotype is unclear,
but it should be pointed out that Meruelo and colleagues have noticed a pref-
erential integration of MuLV in the areas of histocompatibility loci, including
the MHC (17, 18) . Thus, it is possible that the integration of an MuLV in the
regulatory region of the Kk gene has resulted in its failure to be stimulated by
IFN-y signals in the AKR SL3 line . The study of this tumor line may thus pro-
vide insights into tumor escape mechanisms and the mechanism of enhancement
of class I MHC expression by IFN-y .
Summary
T-T tumor hybrids were constructed between the AKR SL3 thymoma and an
H-2-distinguishable thymoma cell line . Hybrids were stimulated with IFN-y to
determine whether the differential augmentation of H-2D vs . H-2K class I anti-
gen expression by AKR SL3 in response to IFN-y was due to effects cis or traps
to the noninducible Kk gene . For each of a large number of hybrids tested, the
expression of H-2D6 , Kb, and Dk , but not Kk , was substantially enhanced by
murine rIFN-y . These results suggested that the lack of induction of theKk gene
was due to an alteration cis to Kk rather than to the presence or absence of K
region-specific, traps-acting negative or positive factors, respectively .
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